A once‑daily oral PARP inhibitor approved for treatment of gBRCA‑mutated HER2‑negative locally advanced or metastatic breast cancer1
Talazoparib (TALZENNA) received a Category 1 recommendation from the National Comprehensive Cancer Network® (NCCN®)2
Category 1 definition: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
NCCN Category 1 Recommendation
Talazoparib is a preferred treatment option for recurrent or Stage IV
HER2-negative patients with a germline BRCA1/2 mutation*
*For patients with HER2-negative disease, strongly consider for germline BRCA1/2 testing.
  1. TALZENNA [prescribing information]. New York, NY: Pfizer Inc; 2018.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed April 15, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.